Essential fatty acids and phospholipase A2 in autistic spectrum disorders.
A health questionnaire based on parental observations of clinical signs of fatty acid deficiency (FAD) showed that patients with autism and Asperger's syndrome (ASP) had significantly higher FAD scores (6.34+/-4.37 and 7.64+/-6.20, respectively) compared to controls (1.78+/-1.68). Patients with regressive autism had significantly higher percentages of 18:0,18:2n-6 and total saturates in their RBC membranes compared to controls, while 24:0, 22:5n-6, 24:1 and the 20:4n-6/20:5n-3 ratio were significantly higher in both regressive autism and ASP groups compared to controls. By comparison, the 18:1n-9 and 20:4n-6 values were significantly lower in patients with regressive autism compared to controls while 22:5n-3, total n-3 and total dimethyl acetals were significantly lower in both regressive autism and ASP groups compared to controls. Storage of RBC at -20 degrees C for 6 weeks resulted in significant reductions in highly unsaturated fatty acid levels in polar lipids of patients with regressive autism, compared to patients with classical autism or ASP, or controls. Patients diagnosed with both autism and ASP showed significantly increased levels of EPA ( approximately 200%) and DHA ( approximately 40%), and significantly reduced levels of ARA ( approximately 20%), 20:3n-6 and ARA/EPA ratio in their RBC polar lipids, when supplemented with EPA-rich fish oils, compared to controls and non-supplemented patients with autism. Patients with both regressive autism and classical autism/Asperger's syndrome had significantly higher concentrations of RBC type IV phospholipase A2 compared to controls. However, patients with autism/ASP, who had taken EPA supplements, had significantly reduced PLA2 concentrations compared to unsupplemented patients with classical autism or ASP.
Lipid Nutrition Group, Institute of Aquaculture, University of Stirling, Stirling, Scotland, FK9 4LA, UK. g.j.bell@stir.ac.uk
J G
JG
Bell
E E
EE
MacKinlay
J R
JR
Dick
D J
DJ
MacDonald
R M
RM
Boyle
A C A
AC
Glen
D020817:Asperger Syndrome / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D001321:Autistic Disorder / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D004739:England; D004910:Erythrocyte Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005228:Fatty Acids, Essential / Q000172:deficiency / Q000378:metabolism* / Q000494:pharmacology; D005395:Fish Oils / Q000494:pharmacology; D006801:Humans; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D013997:Time Factors
D005228:Fatty Acids, Essential; D005395:Fish Oils; D010741:Phospholipases A; D054467:Phospholipases A2